【摘要】：目的:采用Meta分析方法對(duì)胸腺五肽輔助治療慢性阻塞性肺疾病(COPD)的臨床療效及安全性進(jìn)行評(píng)價(jià),為臨床應(yīng)用及輔助用藥管理提供循證參考。方法:計(jì)算機(jī)檢索PubMed、Embase、Cochrane Library、相關(guān)期刊論文(CNKI)、萬方數(shù)據(jù)庫、維普數(shù)據(jù)庫(VIP)、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(各數(shù)據(jù)庫檢索時(shí)間均從建庫至2016年1月),收集胸腺五肽輔助治療COPD的隨機(jī)對(duì)照試驗(yàn)。由2名研究者按照納入與排除標(biāo)準(zhǔn)獨(dú)立篩選試驗(yàn)、提取資料、評(píng)價(jià)方法學(xué)質(zhì)量,采用RevMan 5.3軟件進(jìn)行統(tǒng)計(jì)分析。結(jié)果:共納入16項(xiàng)研究,對(duì)研究進(jìn)行合并分析,結(jié)果顯示,胸腺五肽輔助治療COPD,有效性高于常規(guī)治療組[RR=1.18,95%CI(1.05,1.32),P=0.004],可使患者FEV1得到顯著改善[SMD=0.64,95%CI(0.20,1.09),P=0.005],使患者外周血CD4+水平[WMD=6.25,95%CI(3.02,9.48),P=0.000 1]及CD8+水平顯著降低[WMD=-4.60,95%CI(-7.26,-1.94),P=0.000 7],CD4+/CD8+水平顯著升高[WMD=0.42,95%CI(0.24,0.59),P0.000 01]。結(jié)論:基于現(xiàn)有臨床證據(jù),胸腺五肽輔助治療COPD具有一定臨床療效,但由于納入研究證據(jù)強(qiáng)度較低,存在一定的偏倚風(fēng)險(xiǎn),本研究結(jié)論尚需設(shè)計(jì)嚴(yán)格的臨床對(duì)照試驗(yàn)進(jìn)一步驗(yàn)證。
[Abstract]:Objective: to evaluate the efficacy and safety of thymopeptide in adjuvant treatment of chronic obstructive pulmonary disease (COPD) by means of Meta analysis, and to provide evidence-based reference for clinical application and administration of adjuvant drugs. Methods: PubMed,Embase,Cochrane Library, Chinese periodical full-text database, (CNKI), Wanfang database, and Weip database, (VIP), Chinese biomedical literature database, were searched by computer. The retrieval time of each database was from the establishment of the database to January 2016. A randomized controlled trial of thymopeptide adjuvant therapy for COPD was collected. According to the criteria of inclusion and exclusion, two researchers were selected independently to extract the data and evaluate the quality of methodology. The statistical analysis was carried out with RevMan 5.3 software. Results: the combined analysis of 16 studies showed that the efficacy of thymopeptide adjuvant therapy in COPD, was higher than that in routine treatment group [RR=1.18,95%CI (1.051.32), P0. 004]. FEV1 was significantly improved [SMD=0.64,95%CI (0.20 鹵1.09), P < 0.005] and CD4 level in peripheral blood [WMD=6.25,95%CI (3.02 鹵9.48)]. The levels of CD8 and CD4 / CD8 were significantly decreased [WMD=-4.60,95%CI (-7.261-1.94), P0. 000 7] and CD4 / CD8 increased significantly [WMD=0.42,95%CI (0.240.59), P0.00001]. Conclusion: based on the available clinical evidence, thymopeptide adjuvant therapy for COPD has a certain clinical efficacy, but due to the low intensity of evidence included in the study, there is a certain risk of bias. The conclusion of this study needs to be further verified by a strict clinical controlled trial.
【作者單位】： 黃石市第二醫(yī)院藥劑科;華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬協(xié)和醫(yī)院藥劑科;首都醫(yī)科大學(xué)附屬北京友誼醫(yī)院藥學(xué)部;
【基金】：湖北省自然科學(xué)基金項(xiàng)目(編號(hào):2015CFB225)
【分類號(hào)】：R563.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳君;龐杰;張春彥;許楠;;胸腺五肽配合治療慢性阻肺38例療效觀察[J];中國民族民間醫(yī)藥;2009年02期

2 陳興旺;李健球;;胸腺五肽在重癥肺炎中的應(yīng)用[J];中國醫(yī)藥指南;2010年26期

3 李立林;;胸腺五肽治療重癥肺炎的臨床療效觀察[J];現(xiàn)代診斷與治療;2013年20期

4 陳虹;;胸腺五肽治療66例糖尿病并發(fā)肺結(jié)核患者觀察[J];中國醫(yī)藥指南;2012年10期

5 王愛輝;李艷靜;常占平;曹立華;彭勛;;胸腺五肽對(duì)肺結(jié)核合并糖尿病免疫狀態(tài)影響的研究[J];河北醫(yī)藥;2012年22期

6 呂曉玉;張韶英;;胸腺五肽對(duì)老年慢性阻塞性肺病患者肺功能、細(xì)胞免疫功能及炎癥因子的影響[J];中國現(xiàn)代醫(yī)學(xué)雜志;2014年07期

7 龔澤光;;胸腺五肽治療反復(fù)呼吸道感染的療效觀察[J];內(nèi)蒙古中醫(yī)藥;2009年08期

8 杜永國;何晶;;胸腺五肽輔助治療肺結(jié)核合并糖尿病108例療效觀察[J];海南醫(yī)學(xué);2012年17期

9 孫華明;余學(xué)文;;胸腺五肽預(yù)防老年人呼吸道感染的臨床效果[J];中國臨床保健雜志;2012年06期

10 湯劍平;萬艷;胡川;;胸腺五肽聯(lián)合化療治療肺結(jié)核療效觀察[J];臨床薈萃;2010年17期

，

本文編號(hào)：2304544